ARS Pharmaceuticals Inc
NASDAQ:SPRY
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.48
17.49
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
ARS Pharmaceuticals Inc
ARS Pharmaceuticals Inc
Depreciation & Amortization
ARS Pharmaceuticals Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ARS Pharmaceuticals Inc
NASDAQ:SPRY
|
Depreciation & Amortization
$73k
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Depreciation & Amortization
$8.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
34%
|
CAGR 10-Years
27%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Depreciation & Amortization
$5.6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
23%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Depreciation & Amortization
$219.7m
|
CAGR 3-Years
22%
|
CAGR 5-Years
17%
|
CAGR 10-Years
13%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Depreciation & Amortization
$469.5m
|
CAGR 3-Years
20%
|
CAGR 5-Years
19%
|
CAGR 10-Years
25%
|
|
ARS Pharmaceuticals Inc
Glance View
In the competitive landscape of biotechnology, ARS Pharmaceuticals Inc. positions itself as a transformative player with a focused mission to innovate life-saving medical treatments. The company concentrates on the development of novel therapeutics aimed at treating severe and life-threatening allergic reactions. Its flagship product, a nasal spray designed to deliver epinephrine quickly and effectively, stands as a testament to its innovative efforts. By channeling resources into this potentially groundbreaking delivery mechanism, ARS Pharmaceuticals seeks to address the critical need for patient-friendly solutions in emergency situations, where traditional methods like auto-injectors may be less ideal. Through relentless research and strategic development, the company aims to make these treatments more accessible and user-friendly, potentially expanding their reach within the healthcare market. ARS Pharmaceuticals generates revenue through the commercialization of its therapies, primarily targeting the lucrative segments associated with allergy treatments. Key to their financial strategy is securing regulatory approvals, which opens pathways for product launches and subsequent revenue channels. Furthermore, leveraging strategic partnerships and collaborations within the pharmaceutical industry enhances their market presence. Such alliances allow ARS Pharmaceuticals to tap into established distribution networks, maximizing both reach and revenue potential. Their business model underscores a commitment not only to innovation but also to scalability, aiming to establish a sustainable revenue stream as the demand for efficient allergy treatments grows. This strategic positioning reflects a thorough understanding of market needs and a keen ability to adapt to the ever-evolving healthcare landscape.
See Also
What is ARS Pharmaceuticals Inc's Depreciation & Amortization?
Depreciation & Amortization
73k
USD
Based on the financial report for Dec 31, 2023, ARS Pharmaceuticals Inc's Depreciation & Amortization amounts to 73k USD.
What is ARS Pharmaceuticals Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
-31%
Over the last year, the Depreciation & Amortization growth was -77%. The average annual Depreciation & Amortization growth rates for ARS Pharmaceuticals Inc have been -52% over the past three years , -31% over the past five years .
You don't have any saved screeners yet
